JonathanCorrenMD
Allergy & Immunology • Los Angeles, CAAsthma & Allergic Conditions, Clinical & Laboratory Immunology
Allergy Medical Clinic
Dr. Corren is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
10780 Santa Monica Blvd
Suite 280
Los Angeles, CA 90025Phone+1 310-312-5050Fax+1 310-575-9292
Education & Training
University of Colorado School of Medicine/National Jewish Health (Adult)Fellowship, Allergy and Immunology, 1988 - 1990
University of California Davis HealthResidency, Internal Medicine, 1985 - 1987
University of Southern California/Los Angeles General Medical Center (USC/LA General)Internship, Internal Medicine, 1983 - 1984
University of California San Diego School of MedicineClass of 1983
Certifications & Licensure
CA State Medical License 1984 - 2026
CO State Medical License 1990 - 1993
American Board of Allergy and Immunology Allergy & Immunology
American Board of Internal Medicine Internal Medicine
Awards, Honors, & Recognition
- Top Doctors:LA Area Castle Connolly, 2013
- Top Doctors:Southern California Castle Connolly, 2012
- Super Doctor SuperDoctors.com
Clinical Trials
- Control of Asthma Patients Symptomatic on Inhaled Corticosteroids Start of enrollment: 2006 May 01
- Anti-TSLP (AMG 157) Plus Antigen-Specific Immunotherapy for Induction of Tolerance in Individuals With Cat Allergy Start of enrollment: 2015 Mar 03
Publications & Presentations
PubMed
- 1 citationsPatient-centred composite scores as tools for assessment of response to biological therapy for paediatric and adult severe asthma.Ekaterina Khaleva, Chris Brightling, Thomas Eiwegger, Alan Altraja, Philippe Bégin
The European Respiratory Journal. 2025-03-01 - Tezepelumab for the treatment of chronic spontaneous urticaria: Results of the phase 2b INCEPTION study.Julie McLaren, Yun Chon, Kevin S Gorski, Jonathan A Bernstein, Jonathan Corren
The Journal of Allergy and Clinical Immunology. 2025-02-14 - 3 citationsBiomarkers and clinical outcomes after tezepelumab cessation: Extended follow-up from the 2-year DESTINATION study.Christopher E Brightling, Marco Caminati, Jean-Pierre Llanos, Scott Caveney, Ales Kotalik
Annals of Allergy, Asthma & Immunology. 2024-09-01
Journal Articles
- Editorial How Important Is Adherence to Inhaled Medications Before Starting a Biologic Therapy for Asthma?Jonathan Corren, MD, ScienceDirect
Press Mentions
Add Tezepelumab to SCIT to Improve Cat Allergy Symptoms?November 21st, 2022- Add Tezepelumab to SCIT to Improve Cat Allergy Symptoms?November 18th, 2022
- Fight Cat Allergies with Newest Asthma Drug?October 13th, 2022
- Join now to see all
Professional Memberships
- Member
Other Languages
- Spanish
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
